A unique value proposition to anticipate tumor’s evolution.

ENGAGE WITH US IN A CHANGE OF PARADIGM

A unique value proposition to anticipate tumor’s evolution.

STC Platform

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Access to treatment
Repertoire of targets/ Targets selection
Immunogenicity
Supply Manufacturing

STC allogeneic vaccine

Access to treatment

No tumor biopsy needed, No HLA restriction.

Repertoire of targets/ Targets selection

Mimicking patient’s mechanism of relapse to increase panel of targets. Validation based on proteome. (LC/MS)

Immunogenicity

Enhanced by hyphenation and ghost
cells, maintaining safety.

Supply Manufacturing

“Off-the-shelf” standardized manufacturing, saving cost and time.

Personalized and other cancer vaccine strategies

Access to treatment

Invasive: tumor biopsy needed, HLA restriction.

Repertoire of targets/ Targets selection

Limited / Validation based on gene
extrapolation. (NGC platform)

Immunogenicity

Non immunogenic targets, Potential
safety issues with viral vectors.

Supply Manufacturing

“Patient / Patient”
Complex, long and costly.

BRENUS’ STC IMMUNOTHERAPY IS Administrated IN FIRST LINE

Exemple of treatments with a biological rational to combine with STC 1010

Step 6

Checkpoint inhibitors,ADC, BiSpecificmAb, TLR restores the anticancer immunity

Step 5

5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy.

Step 4

Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors

STC 1010

Step 1

GM-CSF low dose: Recruits APC at injection point and mature DCs.

Step 2

Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation.

Step 3

Chemokyne cytokine TLR : Increase trafficking of T cell

a deep understanding of cancer's complexity

A deep understanding of cancer’s complexity to offer a new kind of Accessible precision treatment in oncology

Reedy to use

For clinical trials & collaborative study

  • GMP Manufacturing ready: Standardized and cost controlled
  • GLP Tax completed, pre IND & pre CTA
    passed
Patent portfolio

Strong protection worldwide

  • Platform patent : Granted in key countries-22 patents (USA, AUS, EU, JAPN..)
  • Product patent Each new drug product generated will be patented
The missing link

TO efficiently treating solid tumors

  • The only technology anticipating the risk of escape and relapse
  • Synergy with standards of care
  • Huge rationale to combine with other
    innovations (ICP, ADC..)
Limitless potential

To position Brenus as a leader in immuno-oncology

  • Leveraging our platform technology to target new indications (AI implementation)

Leveraging
our STC Platform

The technological relay to effectively treat solid tumors and avoid cancer recurrence. Brenus Pharma is now anticipating scientific and clinical collaboration models which aimed at synergizing pipeline development in immuno-oncology.

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens